Print

Dicerna Pharmaceuticals Announces Second DsiRNA Therapeutic Oncology Candidate, Achieves Development Milestone  
8/9/2012 10:43:44 AM

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals Inc., a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technologyâ„¢ and Dicer Substrate siRNA (DsiRNA) molecules, announced today that Kyowa Hakko Kirin Co., Ltd. (TSE: 4151) (KHK) has recognized the successful achievement of an in vivo activity milestone in the development of its second collaborative therapeutic oncology candidate. This achievement triggers an undisclosed milestone payment to Dicerna.